Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma

Zhiqiang Wang, Thiago G. Da Silva, Ke Jin, Xiaoqing Han, Prathibha Ranganathan, Xiaoxia Zhu, Avencia Sanchez-Mejias, Feng Bai, Bin Li, Dennis Liang Fei, Kelly Weaver, Rodrigo Vasquez-Del Carpio, Anna E. Moscowitz, Vadim P. Koshenkov, Lilly Sanchez, Lynne Sparling, Xin-Hai Pei, Dido Franceschi, Afonso Ribeiro, David J RobbinsAlan Livingstone, Anthony J Capobianco

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Esophageal adenocarcinoma ranks sixth in cancer mortality in the world and its incidence has risen dramatically in the Western population over the last decades. Data presented herein strongly suggest that Notch signaling is critical for esophageal adenocarcinoma and underlies resistance to chemotherapy. We present evidence that Notch signaling drives a cancer stem cell phenotype by regulating genes that establish stemness. Using patient-derived xenograft models, we demonstrate that inhibition of Notch by gamma-secretase inhibitors (GSI) is efficacious in downsizing tumor growth. Moreover, we demonstrate that Notch activity in a patient's ultrasound-assisted endoscopic-derived biopsy might predict outcome to chemotherapy. Therefore, this study provides a proof of concept that inhibition of Notch activity will have efficacy in treating esophageal adenocarcinoma, offering a rationale to lay the foundation for a clinical trial to evaluate the efficacy of GSI in esophageal adenocarcinoma treatment.

Original languageEnglish
Pages (from-to)6364-6374
Number of pages11
JournalCancer Research
Volume74
Issue number21
DOIs
StatePublished - Nov 1 2014

Fingerprint

Adenocarcinoma
Amyloid Precursor Protein Secretases
Drug Therapy
Neoplastic Stem Cells
Heterografts
Neoplasms
Clinical Trials
Phenotype
Biopsy
Mortality
Incidence
Growth
Population
Genes
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. / Wang, Zhiqiang; Da Silva, Thiago G.; Jin, Ke; Han, Xiaoqing; Ranganathan, Prathibha; Zhu, Xiaoxia; Sanchez-Mejias, Avencia; Bai, Feng; Li, Bin; Fei, Dennis Liang; Weaver, Kelly; Vasquez-Del Carpio, Rodrigo; Moscowitz, Anna E.; Koshenkov, Vadim P.; Sanchez, Lilly; Sparling, Lynne; Pei, Xin-Hai; Franceschi, Dido; Ribeiro, Afonso; Robbins, David J; Livingstone, Alan; Capobianco, Anthony J.

In: Cancer Research, Vol. 74, No. 21, 01.11.2014, p. 6364-6374.

Research output: Contribution to journalArticle

Wang, Z, Da Silva, TG, Jin, K, Han, X, Ranganathan, P, Zhu, X, Sanchez-Mejias, A, Bai, F, Li, B, Fei, DL, Weaver, K, Vasquez-Del Carpio, R, Moscowitz, AE, Koshenkov, VP, Sanchez, L, Sparling, L, Pei, X-H, Franceschi, D, Ribeiro, A, Robbins, DJ, Livingstone, A & Capobianco, AJ 2014, 'Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma', Cancer Research, vol. 74, no. 21, pp. 6364-6374. https://doi.org/10.1158/0008-5472.CAN-14-2051
Wang Z, Da Silva TG, Jin K, Han X, Ranganathan P, Zhu X et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Research. 2014 Nov 1;74(21):6364-6374. https://doi.org/10.1158/0008-5472.CAN-14-2051
Wang, Zhiqiang ; Da Silva, Thiago G. ; Jin, Ke ; Han, Xiaoqing ; Ranganathan, Prathibha ; Zhu, Xiaoxia ; Sanchez-Mejias, Avencia ; Bai, Feng ; Li, Bin ; Fei, Dennis Liang ; Weaver, Kelly ; Vasquez-Del Carpio, Rodrigo ; Moscowitz, Anna E. ; Koshenkov, Vadim P. ; Sanchez, Lilly ; Sparling, Lynne ; Pei, Xin-Hai ; Franceschi, Dido ; Ribeiro, Afonso ; Robbins, David J ; Livingstone, Alan ; Capobianco, Anthony J. / Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. In: Cancer Research. 2014 ; Vol. 74, No. 21. pp. 6364-6374.
@article{400310ca24df439786ab78e2c6d9f7f0,
title = "Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma",
abstract = "Esophageal adenocarcinoma ranks sixth in cancer mortality in the world and its incidence has risen dramatically in the Western population over the last decades. Data presented herein strongly suggest that Notch signaling is critical for esophageal adenocarcinoma and underlies resistance to chemotherapy. We present evidence that Notch signaling drives a cancer stem cell phenotype by regulating genes that establish stemness. Using patient-derived xenograft models, we demonstrate that inhibition of Notch by gamma-secretase inhibitors (GSI) is efficacious in downsizing tumor growth. Moreover, we demonstrate that Notch activity in a patient's ultrasound-assisted endoscopic-derived biopsy might predict outcome to chemotherapy. Therefore, this study provides a proof of concept that inhibition of Notch activity will have efficacy in treating esophageal adenocarcinoma, offering a rationale to lay the foundation for a clinical trial to evaluate the efficacy of GSI in esophageal adenocarcinoma treatment.",
author = "Zhiqiang Wang and {Da Silva}, {Thiago G.} and Ke Jin and Xiaoqing Han and Prathibha Ranganathan and Xiaoxia Zhu and Avencia Sanchez-Mejias and Feng Bai and Bin Li and Fei, {Dennis Liang} and Kelly Weaver and {Vasquez-Del Carpio}, Rodrigo and Moscowitz, {Anna E.} and Koshenkov, {Vadim P.} and Lilly Sanchez and Lynne Sparling and Xin-Hai Pei and Dido Franceschi and Afonso Ribeiro and Robbins, {David J} and Alan Livingstone and Capobianco, {Anthony J}",
year = "2014",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-14-2051",
language = "English",
volume = "74",
pages = "6364--6374",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma

AU - Wang, Zhiqiang

AU - Da Silva, Thiago G.

AU - Jin, Ke

AU - Han, Xiaoqing

AU - Ranganathan, Prathibha

AU - Zhu, Xiaoxia

AU - Sanchez-Mejias, Avencia

AU - Bai, Feng

AU - Li, Bin

AU - Fei, Dennis Liang

AU - Weaver, Kelly

AU - Vasquez-Del Carpio, Rodrigo

AU - Moscowitz, Anna E.

AU - Koshenkov, Vadim P.

AU - Sanchez, Lilly

AU - Sparling, Lynne

AU - Pei, Xin-Hai

AU - Franceschi, Dido

AU - Ribeiro, Afonso

AU - Robbins, David J

AU - Livingstone, Alan

AU - Capobianco, Anthony J

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Esophageal adenocarcinoma ranks sixth in cancer mortality in the world and its incidence has risen dramatically in the Western population over the last decades. Data presented herein strongly suggest that Notch signaling is critical for esophageal adenocarcinoma and underlies resistance to chemotherapy. We present evidence that Notch signaling drives a cancer stem cell phenotype by regulating genes that establish stemness. Using patient-derived xenograft models, we demonstrate that inhibition of Notch by gamma-secretase inhibitors (GSI) is efficacious in downsizing tumor growth. Moreover, we demonstrate that Notch activity in a patient's ultrasound-assisted endoscopic-derived biopsy might predict outcome to chemotherapy. Therefore, this study provides a proof of concept that inhibition of Notch activity will have efficacy in treating esophageal adenocarcinoma, offering a rationale to lay the foundation for a clinical trial to evaluate the efficacy of GSI in esophageal adenocarcinoma treatment.

AB - Esophageal adenocarcinoma ranks sixth in cancer mortality in the world and its incidence has risen dramatically in the Western population over the last decades. Data presented herein strongly suggest that Notch signaling is critical for esophageal adenocarcinoma and underlies resistance to chemotherapy. We present evidence that Notch signaling drives a cancer stem cell phenotype by regulating genes that establish stemness. Using patient-derived xenograft models, we demonstrate that inhibition of Notch by gamma-secretase inhibitors (GSI) is efficacious in downsizing tumor growth. Moreover, we demonstrate that Notch activity in a patient's ultrasound-assisted endoscopic-derived biopsy might predict outcome to chemotherapy. Therefore, this study provides a proof of concept that inhibition of Notch activity will have efficacy in treating esophageal adenocarcinoma, offering a rationale to lay the foundation for a clinical trial to evaluate the efficacy of GSI in esophageal adenocarcinoma treatment.

UR - http://www.scopus.com/inward/record.url?scp=84909609672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909609672&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2051

DO - 10.1158/0008-5472.CAN-14-2051

M3 - Article

C2 - 25164006

AN - SCOPUS:84909609672

VL - 74

SP - 6364

EP - 6374

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -